# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Addition...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as...
Key Findings from the Phase 3 GBS Trial of ANX005 30 mg/kg Treatment Phase 3 trial informed by dose-ranging Phase 1b trial, ...
The pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Annexon (NASDAQ:ANNX) with a Overweight.